Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 11/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.42 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807021 | 0.83 | ITGAV (0.42) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6221119 | 0.80 | ITGB3 (0.41) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6219556 | 0.80 | ITGB3 (0.43) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL8313372 | 0.78 | ITGB3 (0.41) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6260649 | 0.76 | ITGAV (0.40) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL8333617 | 0.76 | ITGAV (0.40) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6260652 | 0.76 | ITGAV (0.40) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL5848885 | 0.72 | ITGAV (0.52) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL6266843 | 0.72 | ATM (0.35) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL31063405 | 0.72 | ITGAV (0.38) | ITGAVITGB3ITGB1ITGA5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115596-B2 | Thiazole compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1572690-A1 | THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20050004189-A1 | Thiazole compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-06 | — | — | US | disclosed |
| WO-2004058760-A1 | THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058760-A1 | THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | ITGAV 2/4885ITGB3 6/4885ITGB1 11/4885 |
| US-20050004189-A1 | Thiazole compounds as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGAL | ITGAV 5/4885ITGB3 4/4885ITGB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.